NON-INVASIVE MONITORING OF PHYSIOLOGICAL CONDITIONS

• US 20160183829A1
• Filed: 03/04/2016
• Published: 06/30/2016
• Est. Priority Date: 07/14/2010
• Status: Active Grant

• Current Assignee: Mayo Foundation For Medical Education And Research (Mayo Clinic)
• Original Assignee: Mayo Foundation For Medical Education And Research (Mayo Clinic)
• Inventors: Friedman, Paul A., Bennet, Kevin E., Bruce, Charles J., Somers, Virend K.
• Granted Patent: US 9,907,478 B2
• Time in Patent Office: Days
• US Class Current: 1/1
• CPC Class Codes: A61B 5/0006 ECG or EEG signals
• CPC Class Codes: A61B 5/14532 for measuring glucose, e.g. by tissue impedance measurement
• CPC Class Codes: A61B 5/14546 for measuring analytes not otherwise provided for, e.g. ions, cytochromes
• CPC Class Codes: A61B 5/1477 non-invasive
• CPC Class Codes: A61B 5/346 Analysis of electrocardiograms
• CPC Class Codes: A61B 5/35 by template matching
• CPC Class Codes: A61B 5/366 Detecting abnormal QRS complex, e.g. widening

Abstract

This document provides methods and materials related to the non-invasive measurement of analytes in blood.

Claims

1. A method for assessing the level of an analyte within a human, wherein said method comprises obtaining electrocardiogram results from said human and comparing said results to a signal template to obtain an indication of the level of said analyte in said human, wherein said signal template or said electrocardiogram results were generate using a signal averaging technique.

2. The method of claim 1, wherein said signal template and said electrocardiogram results were generate using a signal averaging technique.

3. The method of claim 1, wherein said signal template represents a level of analyte that is within the normal human physiologic range of levels for said analyte.

4. The method of claim 1, wherein said signal template represents a level of analyte that is outside the normal human physiologic range of levels for said analyte.

5. The method of claim 1, wherein said electrocardiogram results, when compared to said signal template, indicate that the level of said analyte in said human is within said normal human physiologic range of levels for said analyte.

6. The method of claim 1, wherein said electrocardiogram results, when compared to said signal template, indicate that the level of said analyte in said human is outside said normal human physiologic range of levels for said analyte.

7. A method for assessing a change in the level of an analyte within a human as compared to a previously determined level of said analyte, wherein said method comprises:

(a) obtaining electrocardiogram results from said human,

(b) comparing said results to a signal template to obtain an indication of the level of said analyte in said human, and

(c) comparing the level of said analyte in said human to said previously determined level of said analyte to determine said change, wherein said change is a change that is not detectable based on visual inspection of an ECG tracing.

8. The method of claim 7, wherein said change is less then 25 percent of the normal physiologic range of said analyte.

9. The method of claim 7, wherein said change is less then 20 percent of the normal physiologic range of said analyte.

10. The method of claim 7, wherein said change is less then 15 percent of the normal physiologic range of said analyte.

11. The method of claim 7, wherein said change is less then 10 percent of the normal physiologic range of said analyte.

12. The method of claim 7, wherein said change is less then 5 percent of the normal physiologic range of said analyte.

13. A method for assessing a change in the level of an analyte within a human as compared to a previously determined level of said analyte, wherein said method comprises:

(a) obtaining an electrical recording result from an organ within said human,

(b) comparing said result to a signal template to obtain an indication of the level of said analyte in said human, and

(c) comparing the level of said analyte in said human to said previously determined level of said analyte to determine said change, wherein said change is a change that is not detectable based on visual inspection of an electrical recording of said organ.

14. The method of claim 13, wherein said organ is a heart.

15. The method of claim 13, wherein said electrical recording result is an ECG tracing.